Table 3.
Serological response to infection based on RBD and NP antibody response.
| LA-SPARTA Infections | |||
|---|---|---|---|
| Previous Infections at Enrollment, n (%) | 53 (26.5%) | ||
| NP Seroconversion, n (%) | 47 (88.7%) | ||
| RBD Seroconversion, n (%) | 49 (92.5%) | ||
| NP & RBD Seroconversion, n (%) | 43 (81.1%) | ||
| Infections During the Study Period | |||
| Reported | Unreported | Total | |
| Infection in un-vaccinated person, n (%) | 2 (1.0%) | 8 (4.0%) | 10 (5.0%) |
| Re-Infection, n | 1 | 4 | 5 |
| NP response, no/minimal RBD response, n | 1 | 1 | 2 |
| RBD response, no/minimal NP response, n | 0 | 4 | 4 |
| Minimal Serological Response, n | 1 | 0 | 1 |
| RBD & NP response, n | 0 | 3 | 3 |
| Breakthrough or Infection in Vaccinated Person, n (%) | 15 (7.5%) | 15 (7.5%) | 30 (15.0%) |
| With serological Data, n | 14 | 15 | 29 |
| Re-Infection, n | 4 | 6 | 10 |
| NP response, no/minimal RBD response, n | 5 | 8 | 13 |
| RBD response, no/minimal NP response, n | 0 | 2 | 2 |
| Minimal Serological Response, n | 2 | 0 | 2 |
| RBD & NP response, n | 7 | 5 | 12 |
Data are represented as the number of participants (n) and the percentage of participants in the cohort or group (%), unless otherwise stated.